New Data Highlight the Positive Impact of Exact Sciences’ Oncotype DX® Test on Patient Care and Healthcare Efficiency

Contributed by: Business Wire

Logo

Tags

Biotechnology

Surgery

Oncology

Health

Medical Devices

Health Technology

Genetics

Clinical Trials

Exact Sciences Corp.

More Like This

Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024

The National Institute for Health and Care Excellence (NICE) Recommends Use of Exact Sciences’ Oncotype DX® Test to Help Guide Chemotherapy Decisions for Node-positive Breast Cancer Patients

Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO®

PR Newswire associated0

Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients

Groundbreaking Study Confirms Clinical Decision Impact of HER2DX® Genomic Assay in Early-Stage HER2-Positive Breast Cancer

REVEAL GENOMICS® HER2DX® Genomic Test to Be Validated in Pivotal ECOG-ACRIN CompassHER2 pCR Trial in HER2+ Breast Cancer

New ‘Super Test’ for Prostate Cancer Developed in the UK by EDX Medical

NEW TESTS TO IDENTIFY HEREDITARY CANCER RISKS TO BE LAUNCHED